Sign in
Taking peopleNo phase

Post-market Follow Up Study on Paragon CRT® 100 (Paflufocon D)

Key facts

Who runs it
CooperVision International Limited (CVIL)
Where
China4 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
250 people, planned
Started
29 Aug 2019
Planned end
31 Dec 2020
Type of study
Interventional
Treatments tested
  • Paragon CRT®100 Contact Lens
Record updated
5 December 2019

Who can take part

Age
8 years and older
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (18)Hide the full registry criteria

Who can take part

  • Patient contact lens refraction should fit within the available parameters of the study lenses (spherical power within -4.00D and the cylinder power within 1.50D)
  • Is willing to comply with the wear and visit schedule
  • Is willing to participate and signed the informed consent form

Who cannot take part

  • Under medications or long-term medications that lead to dry eye with clinical signs or affects vision and corneal curvature
  • Participated in pharmaceutical clinical study 3 months before the date of the screening or participated any other medical devices research study within 30 days of the screening
  • Any ocular abnormalities, undergone corneal surgery, or history of ocular trauma, active corneal infections (corneal inflammation), corneal curvature less than 40.00D or more than 46.00D
  • The eye has the following conditions:; Acute and subacute inflammations or infection of the anterior segment of the eye; Any eye disease, injury, or abnormality that affects the cornea, conjunctiva or eyelids, e.g. dacryocystitis, conjunctivitis, blepharitis and other inflammation, glaucoma, etc; Severe insufficiency of tears (TBUT≤5s); Allergy to any ingredient, such as mercury or thimerosal, in a solution which is to be used to care; Any active corneal infection (bacterial, fungal or viral)
  • Suffering from systemic diseases, resulting in low immunity, or affecting corneal re-shaping (such as acute and chronic sinusitis, diabetes, Down syndrome, rheumatoid arthritis, mental patients, etc.)
  • History of any ocular operations
  • Any other condition not suitable for the study per investigator's judgement
  • Age under 8 years old
  • Best corrected visual acuity less than 1.0D
  • Pregnant, lactating or near-pregnancy
  • Manifested strabismus
  • Abnormal intra-ocular pressure
  • Examination result indicate any contraindication or not suitable for OrthoK lens wear
  • Only eye fulfills inclusion criteria
  • Unable to follow investigator's instruction

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Myopia

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The main objective of this post market clinical study is to evaluate the effectiveness and safety of the Paragon CRT®100 Contact Lens.

The group in the trial

  • Paragon CRT®100 Contact LensTreatment being tested

    participants will wear the Paragon CRT®100 lens with a follow up for no less than 12 months.

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Post-market Follow Up Study on Paragon CRT® 100 (Paflufocon D) Rigid Gas Permeable Contact Lenses for Corneal Refractive Therapy for Temporary Myopic Refractive Power Reduction
Criteria questions
Built from NCT04187599, who can take part
Record updated
5 December 2019